Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

H.C. Wainwright reiterated a Buy rating on Silence Therapeutics (NASDAQ:SLN) stock with a price target of $75.00, representing significant upside from the current price of $5.33. According to ...

WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage ...

Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report) today. The company’s ...

UBS forecasts that Sandoz will likely achieve the lower end of its 24-26% core EBITDA margin target by 2028. To reach the ...

Amgen (NASDAQ:AMGN – Get Free Report) is expected to be issuing its quarterly earnings data after the market closes on ...